XNASGNTA
Market cap91mUSD
Dec 24, Last price
4.99USD
1D
1.90%
1Q
24.75%
IPO
-55.64%
Name
Genenta Science SPA
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+221.27%
CFO
-11m
L+51.05%
Profile
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 11,775 | 11,044 | 5,687 | ||
Unusual Expense (Income) | |||||
NOPBT | (11,775) | (11,044) | (5,687) | ||
NOPBT Margin | |||||
Operating Taxes | (4,853) | 31 | |||
Tax Rate | |||||
NOPAT | (11,775) | (6,191) | (5,719) | ||
Net income | (11,645) 221.27% | (3,625) -34.81% | (5,561) -0.80% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 531 | 28,742 | |||
BB yield | 0.00% | -14.39% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 179 | 116 | 31 | ||
Net debt | (18,776) | (29,795) | (37,240) | ||
| Cash flow | |||||
Cash from operating activities | (11,205) | (7,418) | (6,958) | ||
CAPEX | (27) | (9) | |||
Cash from investing activities | (14,893) | (27) | (9) | ||
Cash from financing activities | 531 | 28,742 | |||
FCF | (12,464) | (5,896) | (6,107) | ||
| Balance | |||||
Cash | 18,776 | 29,795 | 37,240 | ||
Long term investments | |||||
Excess cash | 18,776 | 29,795 | 37,240 | ||
Stockholders' equity | 20,432 | 31,138 | 38,861 | ||
Invested Capital | 1,836 | 1,459 | 1,652 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 18,217 | 18,217 | 18,217 | ||
Price | 4.95 -10.00% | 5.50 -49.82% | 10.96 | ||
Market cap | 90,174 -10.00% | 100,193 -49.82% | 199,686 | ||
EV | 71,398 | 70,398 | 162,446 | ||
EBITDA | (11,732) | (11,038) | (5,682) | ||
EV/EBITDA | |||||
Interest | 2,566 | 12 | |||
Interest/NOPBT | |||||